Displaying results 1 - 10 / 26
results / page
What publication information is included in the service?
Publication name
Authors
Publication channel
Year

Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults

Peer-reviewed
Open access
DOI
10.1080/07853890.2016.1278302
Strandberg, Arto Y.; Khanfir, Houssem; Makimattila, Sari; Saukkonen, Tero; Strandberg, Timo E.; Hoti...
Annals of medicine2017

Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes:Hypothetical Case Studies

Peer-reviewed
Open access
DOI
10.1007/s13300-022-01247-7
Harris, Stewart B.; Parente, Erika B.; Karalliedde, Janaka
Diabetes therapy2022

Insulin glargine use and breast cancer risk: Associations with cumulative exposure

Peer-reviewed
Open access
DOI
10.3109/0284186x.2016.1155736
Peeters, Paul J;Bazelier, Marloes T;Leufkens, Hubert G;Auvinen, Anssi;Auvinen, Anssi;van Staa, Tjeer...
acta oncologica2016

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies:glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

Peer-reviewed
DOI
10.1111/dom.12485
Ritzel, R.; Roussel, R.; Bolli, G. B.; Vinet, L.; Brulle-Wohlhueter, C.; Glezer, S.; Yki-Järvinen, ...
Diabetes obesity and metabolism2015

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine

Peer-reviewed
Strandberg AY.; Hoti FJ.; Strandberg TE.; Christopher S; Haukka J; Korhonen P
Plos One [online]2016

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine

Peer-reviewed
Open access
DOI
10.1371/journal.pone.0151910
Strandberg, Arto Y.; Hoti, Fabian J.; Strandberg, Timo E.; Christopher, Solomon; Haukka, Jari; Korho...
PLoS ONE2016

Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL:1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes

Peer-reviewed
Open access
DOI
10.1111/dom.13105
Ritzel, Robert; Roussel, Ronan; Giaccari, Andrea; Vora, Jiten; Brulle-Wohlhueter, Claire; Yki-Järvin...
Diabetes obesity and metabolism2018

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin:Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

Peer-reviewed
DOI
10.2337/dc14-0990
Yki-Jarvinen, Hannele; Bergenstal, Richard; Ziemen, Monika; Wardecki, Marek; Muehlen-Bartmer, Isabel...
Diabetes care2014

Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus:A post-hoc analysis of a 52-week randomised trial

Peer-reviewed
DOI
10.1016/j.diabres.2019.05.001
Muskiet, M. H. A.; Bunck, M. C.; Heine, R. J.; Corner, A.; Yki-Järvinen, H.; Eliasson, B.; Joles, J....
Diabetes research and clinical practice2019

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling

Peer-reviewed
DOI
10.2337/db12-1773
Varewijck, Aimee J.; Yki-Järvinen, Hannele; Schmidt, Ronald; Tennagels, Norbert; Janssen, Joseph A. ...
Diabetes2013

Insulins NPH, glargine, and detemir, and risk of severe hypoglycemia among working-age adults

Peer-reviewed
Open access
DOI
10.1080/07853890.2016.1278302
2017

Clinical Use of Insulin Glargine 300 U/mL in Adults with Type 2 Diabetes:Hypothetical Case Studies

Peer-reviewed
Open access
DOI
10.1007/s13300-022-01247-7
2022

Insulin glargine use and breast cancer risk: Associations with cumulative exposure

Peer-reviewed
Open access
DOI
10.3109/0284186x.2016.1155736
2016

Patient-level meta-analysis of the EDITION 1, 2 and 3 studies:glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes

Peer-reviewed
DOI
10.1111/dom.12485
2015

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine

Peer-reviewed
2016

All-Cause and Cause-Specific Mortality among Users of Basal Insulins NPH, Detemir, and Glargine

Peer-reviewed
Open access
DOI
10.1371/journal.pone.0151910
2016

Better glycaemic control and less hypoglycaemia with insulin glargine 300 U/mL vs glargine 100 U/mL:1-year patient-level meta-analysis of the EDITION clinical studies in people with type 2 diabetes

Peer-reviewed
Open access
DOI
10.1111/dom.13105
2018

New Insulin Glargine 300 Units/mL Versus Glargine 100 Units/mL in People With Type 2 Diabetes Using Oral Agents and Basal Insulin:Glucose Control and Hypoglycemia in a 6-Month Randomized Controlled Trial (EDITION 2)

Peer-reviewed
DOI
10.2337/dc14-0990
2014

Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus:A post-hoc analysis of a 52-week randomised trial

Peer-reviewed
DOI
10.1016/j.diabres.2019.05.001
2019

Concentrations of Insulin Glargine and Its Metabolites During Long-Term Insulin Therapy in Type 2 Diabetic Patients and Comparison of Effects of Insulin Glargine, Its Metabolites, IGF-I, and Human Insulin on Insulin and IGF-I Receptor Signaling

Peer-reviewed
DOI
10.2337/db12-1773
2013